Guidelines for antimicrobial treatment and prophylaxis of urinary tract infections;Smjernice antimikrobnog liječenja i profilakse infekcija mokraćnog sustava

Lijecnicki Vjesnik

Volumn 126, Issue 7-8, 2004, Pages 169-181

  Škerk, Višnja ^a,h   Krhen, Ivan ^b   Kalenić, Smilja ^c   Francetić, Igor ^d   Baršić, Bruno ^a   Kuzmić, Andreja Cvitković ^e   Derežić, Danijel ^b   Jeren, Tatjana ^a   Kes, Petar ^b   Kraus, Ognjen ^f   Kuvačić, Ivan ^g   Andrašević, Arjana Tambić ^a   Tešović, Goran ^a   Vrčić, Hrvoje ^g  

^a Klinika za Infektivne Bolesti Dr F   (Croatia)

^b KBC Zagreb   (Croatia)

^c Klinicki Zavod za Klinicku I M   (Croatia)

^d Klinika za Unutrasnje B

^e Klinika za Djecje Bolesti Klaiceva

^f Klinika za Urologiju KB Sestre M

^g Klinika za Zenske Bolesti I P   (Croatia)

^h Ministarstva Zdravstva i Socijalne Skrbi RH   (Croatia)

Author keywords

Anti infective agents, urinary therapeutic use, administration and dosage; Practice guidelines; Urinary tract infections microbiology, drug therapy, prevention and control

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; METRONIDAZOLE; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIURIA; BLADDER CATHETERIZATION; CLINICAL FEATURE; CONSENSUS; CROATIA; CYSTITIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DRUG USE; ENTEROBACTER; ENTEROCOCCUS; FEVER; GRAM NEGATIVE BACTERIUM; HEALTH CARE ORGANIZATION; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MONITORING; PATIENT; PREGNANCY; PROSTATITIS; PYELONEPHRITIS; RECIPIENT; RECURRENT DISEASE; REVIEW; SYMPTOM; TREATMENT INDICATION; URINARY TRACT INFECTION; URINE CULTURE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; HUMANS; URINARY TRACT INFECTIONS;

EID: 19944432498     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Sobel DJ, Kaye D. Urinary tract infections. U: Mandell GL, Bennett JE, Dolin RE, ur. Principles and practice of infectious diseases. Philadelphia: Churchil Livingstone; 2000, str. 773-805.
2. Schaeffer AJ. Infections of the urinary tract. U: Walsh PC, ur. Campbell's urology. Philadelphia: Saunders; 2002, str. 515-602.
3. Stamm WE, Stapleton AE. Approach to the patients with urinary tract infection. U: Gorbach SL, Barlett JG, Blacklow NR, ur. Infectious diseases. Philadelphia: WB Saunders Company; 1998, str. 943-54.
4. Schönwald S, Car V, Škerk V, Škalko D. Treatment of urinary tract infections in the outpatient department. Antibiotika Monitor 1986;6:96-8.
5. Škerk V, Schönwald S, Car V. Infekcije urinarnog trakta - klasifikacija, dijagnostika, antimikrobno liječenje. Pharmaca 1995;34:223-34.
6. Škerk V. Infekcije urinarnog trakta. Medicus 1999;8:207-13.
7. Škerk V, Krhen I, Schönwald S, Mareković Z. Prevencija i antimikrobno liječenje infekcija mokraćnog sustava. Infektol Glasn 2000;20:109-17.
8. Škerk V, Krhen I, Schönwald S. Suvremena dijagnostika i liječenje prostatitisa. Infektol Glasn 2000;20:55-62.
9. Štimac G, Dimanovski J, Reljić A. New prospects for chronic prostatitis. Acta Clin Croat 2001;40:109-16.
10. Škerk V, Krhen I, Schönwald S, Mareković Z. Antimikrobno liječenje infekcija mokraćnog sustava. Liječ Vjesn 2001;123:16-25.
11. Krhen I, Škerk V, Schönwald S, Mareković. Klasifikacija, dijagnostika i liječenje sindroma prostatitisa. Lijeć Vjesn 2002;124:89-98.
12. Krhen I, Škerk V, Schönwald S, Jakšić J. Osnovne smjernice za liječenje prostatitisa. Medicus 2002;11:271-5.
13. Krhen I. Sindrom prostatitisa. Medicus 2003;12:205-16.
14. Škerk V. Infekcije mokraćnog sustava - novosti u patogenezi i liječenju. Medicus 2003;12:197-204.
15. Kalenić S, Tambić T, Tambić A, Francetić I. Rezistencija bakterija na antibiotike u Hrvatskoj godine 1998. i 1999. Liječ Vjesn 2000;122:198-9.
16. Tambić T, Tambić A, Kalenić S i sur. Praćenje rezistencije bakterija na antibiotike u Republici Hrvatskoj. Liječ Vjesn 2000;122:160-4.
17. Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2002. godini. Zagreb: Akademija medicinskih znanosti Hrvatske, 2003.
18. Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2003. godini. Zagreb: Akademija medicinskih znanosti Hrvatske, 2004.
19. Škerk V, Popović-Uroić T, Bobinac E, Schönwald S. Promjene antimikrobne rezistencije iz krvi izoliranih sojeva E. coli u desetogodišnjem razdoblju. Pharmaca 1991;29:211-6.
20. Škerk V, Krhen I, Šterk-Kuzmanović N, Baršić B, Vicković N, Schönwald S. Otpornost uzročnika infekcija mokraćnog sustava na antimikrobna sredstva. Pharmaca 2001;39:89-96.
21. Tambić-Andrašević A, Andrašević S, Škerk V. Antibiotic resistance among urinary tract pathogens. Int J Antimicrob Agents 2001;17(Suppl.1):S91.
22. Rušinović M, Vicković N, Krhen I, Škerk V, Šterk-Kuzmanović N, Schönwald S. Antimicrobial resistance of pathogens causing urinary tract infections. Int J Antimicrob Agents 2001;17(Suppl.1):S159.
23. Andriole VT. When to do culture in urinary tract infections. Int J Antimicrob Agents 1999;11:253-5.
24. Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract. Arch Intern Med 1957;100:709-14.
25. Stamm WE, Counts GW, Running KR, Finn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med 1982;307:463-8.
26. Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med 1983;75(1B):53-8.
27. Kunin CM, White LV, Hua TH. A reassessment of the importance of »low-count« bacteriuria in young women with acute urinary symptoms. Ann Intern Med 1993;119:454-60.
28. Norrby SR. Urinary tract infections. U: Finch RG, Greenwood D, Norrby SR, Whitley RJ, ur. Antibiotic and Chemotherapy. Edinburg: Churchill Livingstone; 2003, str. 764-71.
29. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl.1):216-27.
30. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. With modifications by a European Working Party (Norrby SR). General guidelines of urinary tract infection. Germany: The European Society of Clinical Microbiology and Infectious Diseases, Taufkirchen, 1993, str. 240-310.
31. Naber KG, Weidner W. Prostatitis, epididymitis and orchids. U: Cohen J, Powderly WG, ur. Infectious diseses. London: Mosby, 2004, str. 745-52.
32. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5:492-518.
33. Nickel JC. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol 1997;3:38-43.
34. Krieger JN. Prostatitis, epididymitis and orchitis. U: Mandell GL, Bennett JE, Dolin RE, ur. Principles and practice of infectious diseases. Philadelphia: Churchil Livingstone; 2000, str. 1243-50.
35. Meares EM. Urethritis, prostatitis, epididymitis and orchitis. U: Gorbach SL, Barlett JG, Blacklow NR, ur. Infectious diseases. Philadelphia: WB Saunders Company; 1998, str. 954-61.
36. Nickel JC. Prostatitis and related conditions. U: Walsh PC, ur. Campbell's urology. Philadelphia: Saunders; 2002, str. 603-630.
37. Naber KG. Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. 1999;11:189-96.
38. Hooton TM, Scholes D, Hughes JP i sur. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468-74.
39. Stamey TA, Timothy M, Millar M, Mihara G. Recurrent urinary infections in adult women. The role of introital enterobacteria. Calif Med 1971;115:1-19.
40. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001;17:259-68.
41. Fihn SD, Boyko EJ, Normand EH i sur. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol 1996;144:512-20.
42. Fihn SD, Boyko EJ, Chen CL, Normand EH, Yarbro P, Scholes D. Use of spermicide-coated condoms and other risk factors for urinary tract infection caused by Staphylococcus saprophyticus. Arch Intern Med 1998;158:281-7.
43. Smith HS, Hughes JP, Hooton TM i sur. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Clin Infect Dis 1997;25:63-8.
44. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000;182:1177-82.
45. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
46. Schaeffer AJ. Diagnostics and categories of patients. Infection 1992;20 (Suppl.3):S138-42.
47. Hovelius B, Mardh PA. Staphylococcus saprophyticus as a common cause of urinary tract infections. Rev Infect Dis 1984;6:328-37.
48. Schneider PF, Riley TV. Staphylococcus saprophyticus urinary tract infections: epidemiological data from Western Australia. Eur J Epidemiol 1996;12:51-4.
49. Krieger JN. Urinary tract infections: what's new? J Urol 2002;168:2351-8.
50. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
51. Chambers ST. Cystitis and urethral syndromes. U: Cohen J, Powderly WG, ur. Infectious Diseases. London: Mosby, 2004, str. 737-44.
52. Bint AJ, Krause A. Infekcije mokraćnog sustava. U: Walker R, Edwards C. Klinička farmacija i terapija. Zagreb: Školska knjiga, 2004, str. 503-12.
53. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother 2000;46(Suppl.1):23-7.
54. Swedish Urinary Tract Infection Study Group. Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Clin Infect Dis 1995;20:507-13.
55. Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis 1990;12:458-67.
56. Lo Bue AM, Geremia E, Castagna C, Chisari G, Nicoletti G. Sub-MIC ciprofloxacin effect on fimbrial production by uropathogenic Escherichia coli strains. J Chemother 1999;11:357-62.
57. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81.
58. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995;273:41-5.
59. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR 2002; 51(No. RR-6).
60. WHO: Guidelines for the management of sexually transmitted infections. 2003.
61. Francetić I. Liječenje urogenitalnih infekcija u trudnoći. Medicus 2003;12:217-21.
62. Hay P, Pittrof R. Infections in pregnancy. U: Finch RG, Greenwood D, Norrby SR, Whitley RJ, ur. Antibiotic and Chemotherapy. Edinburg: Churchill Livingstone; 2003, str. 772-84.
63. Johnson JR. Pyelonephritis and abscessus of the kidney. U: Cohen J, Powderly WG, ur. Infectious diseses. London: Mosby, 2004, str. 753-63.
64. Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003;22(Suppl.2):65-72.
65. Nicolle LE. Complicated urinary tract infection, including postsurgical and catheter related infections. U: Cohen J, Powderly WG, ur. Infectious diseses. London: Mosby, 2004, str. 763-71.
66. Kunin CM. Urinary tract infections: detection, prevention and management. 5th ed. Baltimore: Williams & Wilkins, 1997.
67. Bergan T. Urinary tract infection. Switzerland: Karger, 1997.
68. Warren JW. Nosocomial urinary tract infections. U: Mandell GL, Bennett JE, Dolin RE, ur. Principles and practice of infectious diseases. Philadelphia: Churchil Livingstone; 2000, str. 3028-39.
69. Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997;53:583-92.
70. Wagenlehner FM, Naber KG. Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl.1):S24-9.
71. Kunin CM, Finkelberg Z. Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients. Ann Intern Med 1970;72:349-56.
72. Škerk V, Schönwald S, Krhen I, Čeljuska-Tošev E, Kopričanec M, Ledić-Drvar D. Klinička primjena piperacilin/tazobaktama. Infektol Glasn 2002;22:159-61.
73. Krhen I, Skerk V, Marekovic Z, Davila NJ. Gentamicin concentrations in urine, cortex and medulla in an acutely obstructed kidney animal model. J Chemother 2001;13:389-94.
74. Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1987;1:823-54.
75. Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991;91(3B):65S-71S.
76. Benčić J, Benčic J. Kako spriječiti bolničke infekcije mokraćnog sustava nastale uslijed primjene katetera? Medicus;2003:12:249-51.
77. Guglielmo BJ, Staller ML, Jacobs RA. Management of candiduria. Int J Antimicrob Agents 1994;4:135-9.
78. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995;20:183-9.
79. Sobel JD, Kauffman CA, McKinsey D i sur. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:19-24.
80. Tsukamoto T, Matsukawa M, Sano M i sur. Biofilm in complicated urinary tract infection. Int J Antimicrob Agents 1999;11:233-6.
81. Smith JW, Jones SR, Reed WP, Tice AD, Deupree RH, Kaijser B. Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med 1979;91:544-8.
82. Eykyn S, Bultitude MI, Mayo ME, Lloyd-Davies RW. Prostatic calculi as a source of recurrent bacteriuria in the male. Br J Urol 1974;46:527-32.
83. Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 1989;110:138-50.
84. Schonwald S, Begovac J, Skerk V. Urinary tract infections in HIV disease. Int J Antimicrob Agents 1999;11:309-11.
85. Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol 1993;149:1046-8.
86. Ulleryd P. Febrile urinary tract infection in men. Int J Antimicrob Agents 2003;22(Suppl.2):89-93.
87. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 1999;84:470-4.
88. European Association of Urology. Guidelines on urinary and male genital tract infections. Arnhem, the Netherlands: Drukkerij Gelderland bv, 2002, str. 49-50.
89. Škerk V, Hadjina G. Chlamydia trachomatis infekcije. Infektol Glasn 1999;19:17-23.
90. Mareković I. Ureaplasma urealyticum i Mycoplasma hominis - dosadašnje spoznaje. Infektol Glasn 2002;22:153-7.
91. Amsden GW. Pharmacology of Azithromycin. U: CTSG Workshop. Brijuni, 19-22. svibnja 2002.
92. Bjerklund Johansen TE, Gruneberg RN, Guibert J i sur. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34:457-66.
93. Naber KG, Busch W, Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000;14:143-9.
94. Krhen I, Škerk V, Puntarić A i sur. Djelotvornost i podnošljivost ciprofloksacina u liječenju bolesnika s kroničnim prostatitisom. Infektol Glasn 2003;23:17-21.
95. Čičin-Šajn D, Kalauz N. Liječenje benigne hiperplazije prostate i kroničnog prostatitisa mikrovalnom termoterapijom. Docum Urol 1998;34:457-66.
96. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M. Chronic prostatitis: a thorough search for etiologicaily involved microorganisms in 1,461 patients. Infection 1991;19(Suppl.3):S119-25.
97. Skerk V, Schonwald S, Krhen I i sur. Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002;19:471-4.
98. Skerk V, Krhen I, Schonwald S i sur. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004;21: u tisku.
99. Gomberg M. Perzistentna klamidijska infekcija. Medicus 2003;1-2:179-88.
100. Skerk V, Schonwald S, Strapac Z i sur. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. J Chemother 2001;13:176-81.
101. Skerk V, Schonwald S, Krhen I i sur. Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2001;13:664-5.
102. Skerk V, Schonwald S, Krhen I i sur. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003;21:457-62.
103. Skerk V, Krhen I, Lisic M i sur. Azithromycin: 4,5- or 6.0- gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis - a randomized study. J Chemother 2004; 16: u tisku.
104. Skerk V, Krhen I, Lisic M i sur. Comparative randomized pilot study of azithromycin and doxycycline eficacy and tolerability in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004;24:188-191.
105. Skerk V, Marekovic I, Markovinovic L i sur. Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum. Chemotherapy 2004;24:188-191.
106. Blažeković M. Klinička primjena klaritromicina - može li se proširiti? Infektol Glasn 2003;23:67-71.
107. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panon C, Adamakis I, Giamarellou H. Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis. J Urol 2001;165:97-9.
108. Škerk V, Krhen I, Schönwald S i sur. Klaritromicin u liječenju kroniǒnog prostatitisa izazvanog bakterijom Chlamydia trachomatis - probno ispitivanje. Pharmaca 2001;39:193-201.
109. Skerk V, Schonwald S, Krhen I i sur. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2002;14:384-9.
110. Krhen I, Škerk V, Schönwald S, Jakšić J. Otkrivanje i liječenje prostatitisa. Medix 2002;8:100-2.
111. Skerk V, Schonwald S, Granic J i sur. Chronic prostatitis caused by Trichomonas vaginalis - diagnosis and treatment. J Chemother 2002;14:537-8.
112. Vergs J. Les prostatites a trichomonas formes rondes (T.F.R.). J Urol Nephrol (Paris) 1979;85:357-61.
113. Puntarić A, Iskustva u liječenju kronične klamidijske infekcije. Medicus 2003;12:243-6.
114. Raz R. Asymptomatic bacteriuria. Clinical significance and management. Int J Antimicrob Agents 2003;22(Suppl.2):45-7.
115. Hanson LA. Prognostic indicators in childhood urinary infections. Kidney Int 1982;21:659-67.
116. Shortliffe LM. Asymptomatic bacteriuria: should it be treated? Urology 1986;27(Suppl.2):19-25.
117. Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol 1989;73:576-82.
118. MacLean AB. Urinary tract infection in pregnancy. Int J Antimicrob Agents 2001;17:273-6; discussion 276-7.
119. Whitworth JA. Management of asymptomatic bacteriuria. Aust N Z J Med 1981;11:321-8.
120. Sidor TA, Resnick MI. Urinary tract infection in children. Pediatr Clin North Am 1983;30:323-32.
121. MacFarlane DE. Catheter-associated urinary tract infections. Part I: Epidemiology, pathogenesis and bacteriology. West Indian Med J 1984;33:146-50.
122. Garibaldi RA, Burke JP, Dickman ML, Smith CB. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med 1974;291:215-9.
123. Uehling DT, Smith J, Meyer J, Bruskewitz R. Impact of an intermittent catheterization program on children with myelomeningocele. Pediatrics 1985;76:892-5.
124. Zhanel GG, Harding GK, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 1991;13:150-4.
125. Geerlings SE, Stolk RP, Camps MJ i sur. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 2000;23:744-9.
126. Wheat LJ. Infection and diabetes mellitus. Diabetes Care 1980;3:187-97.
127. Harding GK, Zhanel GG, Nicolle LE, Cheang M. Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002;347:1576-83.
128. Geerlings SE, Meiland R, Hoepelman AI. Treatment of asymptomatic bacteriuria in diabetic women. N Engl J Med 2003;348:957-8.
129. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003;22(Suppl.2):35-43.
130. Geerlings SE, Stolk RP, Camps MJ i sur. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000;23:1737-41.
131. Geerlings SE, Stolk RP, Camps MJ i sur. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001;161:1421-7.
132. Geerlings SE, Meiland R, Hoepelman AI. Antibiotic treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, u tisku.
133. Schönwald S, Škerk V, Puntarić A i sur. Djelotvornost i podnošljivost profilaktičke primjene nitrofurantoina u žena s rekurentnim nekompliciranim infekcijama donjeg mokraćnog sustava. Infektol Glasn 2002;22:97-100.
134. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997;157:935-9.
135. McGeachic J. Recurrent infection of the urinary tract: reinfection of recrudescence? Br Med J 1966;1:952-4.
136. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001;135:9-16.
137. Schaeffer AJ, Stuppy BA. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. J Urol 1999;161:207-11.
138. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post-menopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
139. Boris S, Suarez JE, Vazquez F, Barbes C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect Immun 1998;66:1985-9.
140. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322:1571.
141. Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother 1989;33:92-8.
142. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 1998;339:1085-6.
143. Grabe M. Controversies in antibiotic prophylaxis in urology. Int J Antimicrob Agents 2004;23(Suppl.1):S17-23.
144. Taylor EW. Abdominal and other surgical infections. U: Finch RG, Greenwood D, Norrby SR, Whitley RJ, ur. Antibiotic and Chemotherapy. Edinburg: Churchill Livingstone; 2003, str. 526-43.
145. Norrby SR. Principles of chemophrophylaxis. U: Finch RG, Greenwood D, Norrby SR, Whitley RJ, ur. Antibiotic and Chemotherapy. Edinburg: Churchill Livingstone; 2003, str. 120-2.
146. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992;326:281-6.
147. Nielsen OS, Madsen PO. Importance and timing of prophylactic antibiotics in urology with a special reference to growth and kill rates of E. coli in genitourinary organs. J Urol 1982;128:608-14.
148. Naber KG, Bergman B, Bishop MC i sur. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001;40:576-88.
149. Johansen TE. Nosocomially acquired urinary tract infections in urology departments. Why an international prevalence study is needed in urology. Int J Antimicrob Agents 2004;23(Suppl.1):S30-4.
150. Lohr JA, Downs SM, Schlager TA. Urinary tract infections. U: Long SS, Pickering LK, Prober CG (ur). Principles and Practice of Pediatric Infectious Diseases. New York: Churchill Livingstone, 2003:323-8.
151. Schlager TA. Urinary tract infections in children younger than 5 years of age: epidemiology, diagnosis, treatment, outcomes and prevention. Paediatr Drugs 2001;3:219-27.
152. Hiraoka M, Hashimoto G, Tsuchida S, Tsukahara H, Ohshima Y, Mayumi M. Early treatment of urinary infection prevents renal damage on cortical scintigraphy. Pediatr Nephrol 2003;18:115-8.
153. Hari P, Mantan M, Bagga A. Management of urinary tract infections. Indian J Pediatr 2003;70:235-9.
154. Biyikli NK, Alpay H, Ozek E, Akman I, Bilgen H. Neonatal urinary tract infections: analysis of the patients and recurrences. Pediatr Int 2004;46:21-5.
155. Al-Orifi F, McGillivray D, Tange S, Kramer MS. Urine culture from bag specimens in young children: are the risks too high? J Pediatr 2000;137:221-6.
156. Hellerstein S. Antibiotic treatment for urinary tract infections in pediatric patients. Minerva Pediatr 2003;55:395-406.
157. Chong CY, Tan AS, Ng W, Tan-Kendrick A, Balakrishnan A, Chao SM. Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatr 2003;92:291-6.
158. Goldraich NP, Manfroi A. Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. Pediatr Nephrol 2002;17:173-6.
159. Fanos V, Cataldi L. Cefixime in urinary tract infections with special reference to pediatrics: overview. J Chemother 2001;13:112-7.
160. Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L, Amir J. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection. Arch Dis Child 2003;88:215-8.
161. Michael M, Hodson EM, Craig JC, Martin S, Mayer VA. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database of Systematic Reviews 2003;(1):CD 003966.
162. Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child 2002;87:118-23.
163. Keren R, Chan E. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infections in children. Pediatrics 2002;109:E70-0.
164. Kaneko K, Ohtomo Y, Shimizu T, Yamashiro Y, Yamataka A, Miyano T. Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux. Pediatr Nephrol 2003;18:468-70.
165. Stranieri G, Zampogna S, Ielapi V i sur. Cefixime for the prophylaxis of urinary tract infections in children with malformative uropathies: an open study. Eur Rev Med Pharmacol Sci 2003;7:57-64.
166. Nuutinen M, Uhari M. Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol 2001;16:69-72.
167. Williams GJ, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database of Systematic Reviews 2001;(4):CD 001534.
168. Le Saux N, Pham B, Moher D. Evaluating the benefits of antimicrobial prophylaxis to prevent urinary tract infections in children: a systematic review. CMAJ 2000;163:523-9.